Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

AstraZeneca, Oxford aim to produce Omicron-targeted vaccine

Published 12/21/2021, 04:30 PM
Updated 12/21/2021, 06:45 PM
© Reuters. FILE PHOTO: A doctor shows vials of AstraZeneca's COVID-19 vaccine in his general practice facility, as the spread of the coronavirus disease (COVID-19) continues, in Vienna, Austria May 13, 2021. REUTERS/Leonhard Foeger

(Reuters) -AstraZeneca Plc said on Tuesday it is working with Oxford University to produce a vaccine for the Omicron coronavirus variant, joining other vaccine-makers who are looking to develop the variant-specific vaccine.

"Together with Oxford University, we have taken preliminary steps in producing an Omicron variant vaccine, in case it is needed and will be informed by emerging data," a spokesperson for the company said in a statement.

Oxford did not immediately respond to a request for comment outside business hours.

The Financial Times first reported the news, citing Sandy Douglas, a research group leader at Oxford.

"Adenovirus-based vaccines (such as that made by Oxford/AstraZeneca) could in principle be used to respond to any new variant more rapidly than some may previously have realised," Douglas told FT.

A lab-study last week found that AstraZeneca (NASDAQ:AZN)'s antibody cocktail Evusheld retained neutralising activity against the Omicron variant.

Vaccine makers Pfizer/BioNTech and Moderna (NASDAQ:MRNA) also previously said they were working on Omicron- specific COVID-19 vaccines. Moderna said hopes to start clinical trials early next year.

Latest comments

everyone knows that the pcr test is a fraud right? it's highly inaccurate with many false positive results
this is a perpetual money making machine for the pharmaceutical companies. new variant new vaccine more money more profits
🤡🤡🤡🤣
boogeyman omicron will show very dangerous better you run and start having your first shot of vaccine lol
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.